Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | Personalized medicine in early-stage TNBC

Oleg Gluz • 10 Sep 2022
ESMO 2022
Breast Cancer Capecitabine

Oleg Gluz, MD, Evang. Krankenhaus “”Bethesda”” Klinik, Mönchengladbach, Germany, discusses the implementation of personalized medicine in early breast cancer. Dr Gluz touches on the role of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) as a prognostic marker for treatment escalation/de-escalation. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Oleg Gluz

0:49
Breast cancer at ESMO 2023: ADCs and MONARCH 3
Oleg Gluz • 22 Oct 2023
1:38
Unanswered questions in the use of adjuvant therapy in early breast cancer
Oleg Gluz • 22 Nov 2023
3:06
Prognostic score in early HR+/HER2- breast cancer: RS, factors, mutations, histology
Oleg Gluz • 22 Oct 2023
1:35
Difficulties of defining high-risk breast cancer
Oleg Gluz • 10 Sep 2022

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals